Reasons to Retain Doximity Stock in Your Portfolio for Now

Doximity shares are down 35.9% year to date as AI adoption accelerates but has yet to translate into faster company-wide growth. First-quarter revenue rose 7% year over year to $157 million, while fiscal 2027 revenue consensus is $675.7 million (+4.8%) and adjusted EPS consensus is $1.33 (-12.5%); estimates have fallen 9 cents in 60 days. AI workflow prescribers grew more than 30% year over year, but adjusted gross margin fell to 88% from 91% as AI-compute spending rose, with fiscal 2027 gross margins expected in the mid-to-high 80% range.

Analysis

The key underwriting gap is conversion, not adoption: high usage and hospital interest can strengthen Doximity’s strategic position without creating near-term revenue if budgets remain committed to legacy pharma placements or AI pilots do not become paid deployments. That leaves DOCS exposed to an unfavorable timing mismatch—compute costs are already visible in margins, while incremental AI revenue is not yet evident in consolidated growth. Established EHR and clinical-workflow vendors, including Epic and Microsoft’s Nuance business, can also bundle AI into existing relationships, limiting Doximity’s ability to capture standalone enterprise budgets even if the product performs well in evaluations.

Near term (days to the next results), estimate cuts and the sharp prior share-price decline argue against chasing a fresh short; adoption metrics may support a relief rally. Over 1–3 months, focus on paid AI conversion, customer renewal duration, and whether pharma spending is broadening beyond a few accounts. Over 6–18 months, the upside case requires AI to diversify revenue and eventually offset compute costs; the downside is a persistently slower-growth ad platform carrying a more expensive cost base. The contrarian point: physician engagement is a leading indicator, not proof of monetization, but the market may also be over-penalizing investment before the upfront selling cycle reflects new products. The thesis turns if revenue growth reaccelerates alongside improving gross-margin trajectory; continued estimate reductions or margin deterioration without disclosed AI revenue would confirm downside risk.

Key Decisions for Investors

• Maintain an underweight/avoid-add stance on DOCS rather than press an outright short after the large drawdown. Reassess after the next earnings report, prioritizing paid AI revenue or bookings, renewal duration, and gross margin—not usage growth alone.
• Set a 1–3 month alert for evidence that AI demand is converting beyond pilots and a narrow set of pharma accounts. Broad-based paid adoption plus stabilizing margins would invalidate the cautious view and justify covering underweight exposure.
• If revenue growth remains near the current low-single-digit outlook while AI costs hold margins in the mid-to-high 80% range, retain downside protection or reduce exposure; a further estimate reset without a corresponding AI monetization disclosure is the principal bearish catalyst.
• Do not substitute GMED, WST, or KRMD as direct hedges for DOCS: their business drivers differ. Any DOCS options position should wait for current implied volatility and event pricing, which are not provided.